Twist Bioscience Corp — Director's Dealing 2022

Feb 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Twist Bioscience Corp (TWST)
CIK: 0001581280
Period of Report: 2022-02-07

Reporting Person: Mai Xiaoying (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-02-07	Common Stock	A	13539	—	Acquired	13539	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-07	Director Stock Option (right to buy)	$60.33	A	10588	Acquired	2029-07-22	Common Stock (10588)	Direct
2022-02-07	Director Stock Option (right to buy)	$60.33	A	11297	Acquired	2030-02-03	Common Stock (11297)	Direct
2022-02-07	Director Stock Option (right to buy)	$189.96	A	973	Acquired	2031-02-02	Common Stock (973)	Direct

Footnotes

F1: Each equity is fully vested at the time of grant, but represent equity awards for prior annual meetings in 2019, 2020 and 2021 that the Company was not able to grant. If the grants had been made at the time of the prior annual meetings, each grant would have vested upon the earlier of (1) the 1 year anniversary of the date of grant or (2) the next annual meeting.